Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.687 enrolled

Overview

In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.

Study Type

OBSERVATIONAL

Enrollment

687

Conditions

Cardiovascular Diseases Coronary Artery Disease

Interventions

AtorvastatinDRUG

Atorvastatin, 10- 80 mg, once daily, 6 month treatment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients, who eligible to sign informed consent; * Patients with indications to lipid lowing therapy, according to local product document. * Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study; * Patients with LDL levels: \> 3,5 mmol/l Exclusion Criteria: * Individual intolerance of atorvastatin, in accordance to local product document.

Outcomes

Primary Outcomes

Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit

Time frame: Month 6

Secondary Outcomes

Percentage of Participants Achieving LDL Level ≤ 100 mg/dL at the 1 Month Visit

Time frame: Month 1

Change From Baseline in Lipid Parameters

Lipid parameters include HDL cholesterol, LDL cholesterol, total cholesterol, and total triglycerides. Change = Month 6 value minus baseline

Time frame: Month 6

Percent Change From Baseline in Lipid Parameters

Percent change from baseline calculated as: 100\*(change at Month X)/(baseline value).

Time frame: Month 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.